Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Philip, Clingan"'
Autor:
Thomas Hansen, Jonathon Hill, Gary Tincknell, Derrick Siu, Daniel Brungs, Philip Clingan, Lorraine Chantrill, Udit Nindra
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 6, Pp 1247-1260 (2024)
The treatment of early-stage non-small cell lung cancer (NSCLC) is becoming increasingly complex. Standard of care management for the past decade has been adjuvant chemotherapy following curative intent resection regardless of nodal status or tumour
Externí odkaz:
https://doaj.org/article/452da1eb38d6484bbf431bf85daa2605
Autor:
Michael Boyer, Rina Hui, Damien Urban, Philip Clingan, Wu-Chou Su, Celine Devaux, Shirish Gadgeel, Marina Garassino, Lance Leopold, Jeannie Daniel, Mihaela C. Munteanu, Ayman Samkari, Yiwen Luo, Delvys Rodriguez Abreu
Publikováno v:
BMC Cancer, Vol 23, Iss S1, Pp 1-12 (2024)
Abstract Background The combination of the checkpoint inhibitor (CPI) pembrolizumab and platinum-based chemotherapy is effective frontline therapy for advanced non-small cell lung cancer (NSCLC) lacking targetable mutations. Indoleamine 2,3- dioxygen
Externí odkaz:
https://doaj.org/article/f859d06395444ff68173b8d586898c31
Autor:
Jayesh Desai, Stephane Dalle, Jermaine Coward, Daniel Brungs, Andrew Mant, Margaret McGrath, Andrea Tazbirkova, Piotr Koralewski, Iwona Lugowska, Arunee Dechaphunkul, Virote Sriuranpong, James Oliviero, Philip Clingan, Rahul Ladwa, Eva Muñoz-Couselo, Henri Montaudié, Miguel-Ángel Berciano-Guerrero, Dean Laurence Harris, Susan Arnold, Samuel Fourie, Andriy Kurochkin, Daniel R Malan, Vinay Sharma, Hong Shue, Chaiyut Charoentum, Oleksandr Dudnichenko
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background Programmed cell death receptor-1 (PD-1)-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) cases ineligible for curative surgery or radiation. Notwithstanding, some patients ex
Externí odkaz:
https://doaj.org/article/ba79bd85b8124e27b03c0ee657e71ed1
Autor:
Thiru Prasanna, Laeeq Malik, Robert D. McCuaig, Wen Juan Tu, Fan Wu, Pek Siew Lim, Abel H. Y. Tan, Jane E. Dahlstrom, Philip Clingan, Eugene Moylan, Jeremy Chrisp, David Fuller, Sudha Rao, Desmond Yip
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
ObjectiveLysine-Specific Demethylase-1 (LSD1) is overexpressed in breast cancer cells and facilitate mesenchymal properties which may contribute to therapeutic resistance and cancer progression. The purpose of this study was to investigate the safety
Externí odkaz:
https://doaj.org/article/7ccd363096da4ed794e3ded46a555829
Autor:
Dean Harris, Daniel Brungs, Rahul Ladwah, Andrew Mant, Margaret McGrath, Andrea Tazbirkova, Andrey Akopov, Natalia Fadeeva, Boris Kasparov, Nadezhda Kovalenko, Vadim Kozlov, Fedor Moiseenko, Vasiliy Oschepkov, Piotr Koralewski, Dariusz Kowalski, Iwona Lugowska, Chaiyut Charoentumn, Arunee Dechaphunkul, Virote Sriuranpong, James Oliviero, Philip Clingan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/115fbf3202dd41a198c2223d3da6fcbc
Autor:
Daniel Brungs, Morteza Aghmesheh, Paul de Souza, Weng Ng, Wei Chua, Martin Carolan, Philip Clingan, Emma Healey, June Rose, Tameika Tubaro, Marie Ranson
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017)
Abstract Background/Aim Right sided colon cancer (RsCC) is proposed to be a distinct disease entity to left sided colon cancer (LsCC). We seek to confirm primary tumour location as an independent prognostic factor in locoregional colorectal cancer. M
Externí odkaz:
https://doaj.org/article/fffc72a41ca54a42a309af1336d753b5
Autor:
Frank Seebach, Naiyer A. Rizvi, Semra Paydas, Chieh I. Chen, Ahmet Sezer, Mustafa Ozguroglu, Oleg Gladkov, George D. Yancopoulos, Irfan Cicin, David M. Weinreich, Israel Lowy, Mahmut Gumus, Virote Sriuranpong, P. Rietschel, Kristina McGuire, Dmitry Bentsion, Marina Nechaeva, Saadettin Kilickap, Miranda Gogishvili, Bo Gao, Siyu Li, Igor Bondarenko, S. Lee, Giuseppe Gullo, Haci Mehmet Turk, Philip Clingan, Tamta Makharadze
Publikováno v:
The Lancet. 397:592-604
We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the first-line treatment of advanced non-small-cell lung cancer with programmed cell death ligand 1 (PD-L1) of at least 50%.In EMPOWER-Lung 1, a multicentre, open-label, global,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b83816747afb1802082cc7a5418f2da5
https://doi.org/10.1016/s0140-6736(21)00228-2
https://doi.org/10.1016/s0140-6736(21)00228-2
Autor:
Enriqueta Felip, Emilio Esteban, Ross Jennens, Helge Bischoff, Edward B. Garon, Jhanelle E. Gray, Nir Peled, Shirish M. Gadgeel, Giovanna Speranza, Steven Francis Powell, J. Yang, Delvys Rodriguez-Abreu, Rina Hui, Tuba Bas, Manuel Domine, Martin Reck, Silvia Novello, Maximilian Hochmair, Takayasu Kurata, Philip Clingan, Marina Chiara Garassino, M. Catherine Pietanza, Susanna Yee Shan Cheng, Belén Rubio-Viqueira, Michael Boyer, Francesco Grossi
Publikováno v:
Journal of Clinical Oncology. 38:1505-1517
PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒sm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee3fac31820bd23cebc2d25b951fed70
https://doi.org/10.1200/jco.19.03136
https://doi.org/10.1200/jco.19.03136
Autor:
Suresh S. Ramalingam, Lei He, Mária Szilasi, Martin Dunbar, Bruce A. Bach, Ramaswamy Govindan, Julien Mazieres, Silvia Novello, R. Bernabé, Xin Huang, Everett E. Vokes, Peter Ansell, Salih Zeki Guclu, Dmitry Bentsion, Philip Clingan, Zanete Zvirbule, Jair Bar, Vasudha Sehgal, Konstantinos N. Syrigos, Jaimee Glasgow, Lauren Averett Byers
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(32)
PURPOSE Squamous non–small-cell lung cancer (sqNSCLC) is genetically complex with evidence of DNA damage. This phase III study investigated the efficacy and safety of poly (ADP-ribose) polymerase inhibitor veliparib in combination with conventional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::514dc6ffd32107af8c370ecf50e3b82f
https://pubmed.ncbi.nlm.nih.gov/34436928
https://pubmed.ncbi.nlm.nih.gov/34436928
Autor:
Richard David Ranson, Paul de Souza, Morteza Aghmesheh, Marie Ranson, Rebecca Jokela, Philip Clingan, Stephen P. Ackland, Daniel Brungs, Suzanne Parker, M B Garg
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 15:151-157
Background 5-Fluorouracil (5-FU) is administered with leucovorin (LV) to enhance clinical activity. However, simultaneous administration is not feasible due to their chemical incompatibility, so conditions for the maximum possible beneficial interact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fac6155fd0fcfd3d7ad4dd30c21a806
https://doi.org/10.1111/ajco.13144
https://doi.org/10.1111/ajco.13144